Regulus Therapeutics Inc (Nasdaq: RGLS), a United States-based biopharmaceutical company, has received Orphan Drug Designation from the United States Food and Drug Administration (FDA) for its RGLS4326 intended for the treatment of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), it was reported on Wednesday.
Jay Hagan, Regulus CEO, said, 'We are pleased RGLS4326 has been granted Orphan Drug Designation by FDA, this is an important milestone for our ADPKD program and our efforts to address the significant unmet medical needs with this disease.'
The US FDA Office of Orphan Drug Products offers orphan status to drugs aimed at treating rare disorders that affect less than 200,000 people in the United States. The designation provides certain potential benefits to the drug developer, including seven years of market exclusivity upon FDA approval, prescription drug user fee waivers and tax credits for qualified clinical trials.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval